Search Browse Earnings

Anbio Biotechnology — SlamSEC

Anbio Biotechnology

Nasdaq:NNNN

In Vitro & In Vivo Diagnostic Substances·FRANKFURT AM MAIN, 2M

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$23.5M

FY 2024

Adj. EBITDA

—

Net Income

$10.0M

42.5% margin

FY 2024

EPS (Diluted)

$100112.00

FY 2024

Stock Price

$20.51

-9.0%

2026-03-13

52W Range

$5.89 – $55.65

P/E Ratio

0.0x

Market Cap

—

Cash

$9.7M

FY 2024

Total Debt

—

Net Cash

$9.7M

FY 2024

Enterprise Value

—

Debt / EBITDA

—

EV / EBITDA

—

Employees

—